Early Immunotherapy for Cancer: Benefits & Risks

The landscape of cancer treatment is evolving, with immunotherapy increasingly being utilized earlier in the course of the disease. This shift, moving beyond its traditional role as a last resort, is prompting researchers to carefully examine both the benefits and potential risks associated with this approach.

Immunotherapy harnesses the power of the body’s own immune system to recognize and destroy cancer cells. Unlike chemotherapy or radiation, which directly target rapidly dividing cells – both cancerous and healthy – immunotherapy aims to strengthen the immune system’s ability to distinguish between self and non-self, allowing it to selectively attack cancer. As explained by Cleveland Clinic, this is achieved by either stimulating the immune system to produce more cancer-fighting cells or by helping the body’s existing immune cells more effectively locate and destroy cancer.

Historically, immunotherapy was often reserved for patients with advanced cancers that had stopped responding to other treatments. However, recent studies suggest that administering immunotherapy before or after surgery – known as neoadjuvant or adjuvant immunotherapy, respectively – can significantly reduce the risk of the disease returning. This is particularly encouraging, as earlier intervention often leads to better outcomes.

The most common form of immunotherapy involves immune checkpoint inhibitors. These drugs work by releasing brakes on the immune system, allowing it to mount a stronger attack against cancer cells. While highly effective for many, this broad activation of the immune system can also lead to unintended consequences. As Harriet Kluger, MD, of Yale Cancer Center, explains, “Immune checkpoint inhibitors…can activate immune cells indiscriminately, including some that cause inflammation in normal organs.”

These side effects, often referred to as immune-related adverse events (irAEs) or immunotoxicities, can range from mild rashes and fatigue to more severe complications affecting the neurologic, cardiac, pulmonary, or gastrointestinal systems. Diarrhea, in particular, can become life-threatening. The unpredictable nature of these side effects – their potential to occur at any time and affect any organ – underscores the importance of careful monitoring and proactive management.

Researchers are now focused on identifying irAEs early and developing strategies to minimize risks while maximizing the benefits of immunotherapy. This includes investigating ways to selectively inhibit the activity of immune cells that are causing damage to healthy tissues. The goal is to fine-tune the immune response, ensuring it remains focused on cancer cells while sparing normal organs from collateral damage.

The success of immunotherapy has been particularly notable in melanoma. Mario Sznol, MD, also of Yale Cancer Center, and Dr. Kluger were pioneers in developing immunotherapies for metastatic melanoma, dramatically increasing the five-year overall survival rate from 5% to over 50%. This remarkable improvement highlights the transformative potential of immunotherapy in cancer treatment.

The increasing use of immunotherapy across various cancer types reflects a growing understanding of its potential and a commitment to improving patient outcomes. While the benefits are substantial, it’s crucial to acknowledge and address the associated risks. Ongoing research is essential to refine treatment strategies, identify patients who are most likely to benefit, and develop effective methods for managing irAEs. As immunotherapy continues to evolve, it promises to play an increasingly important role in the fight against cancer.

The emergence of immunotherapy as a fourth pillar of cancer treatment – alongside surgery, radiation, and chemotherapy – signifies a paradigm shift in how we approach this disease. It represents a move towards harnessing the body’s own defenses, offering a potentially more targeted and effective way to combat cancer. However, careful consideration of both the benefits and risks remains paramount to ensure the best possible outcomes for patients.